Articles tagged with Parkinsons Disease
A Finnish clinical imaging study found that rest tremor in Parkinson's disease is associated with relatively well-preserved dopamine function, challenging the long-held assumption of greater dopamine loss. The study analyzed data from 414 patients and demonstrated a clear correlation between higher dopamine transporter binding and tremor.
The Robert A. Winn Excellence in Clinical Trials Award Program is expanding its career development award to include neuropsychiatry researcher-physicians. This expansion aims to improve clinical trial enrollment and represent diverse patient populations affected by complex disorders.
Researchers at the University of Edinburgh have developed a method to transform post-consumer plastic into L-DOPA, a frontline medication for Parkinson's disease. The process harnesses the power of bacteria to break down PET waste and produce L-DOPA, providing a sustainable solution to the production of pharmaceuticals.
The ISSCR has launched a new continuing education course on stem cell therapies for Parkinson’s disease, addressing the need for clinicians to provide accurate information on emerging treatments. The course features expert faculty and patient perspectives, and is available through a free and paid pathway.
Researchers created the most comprehensive single-cell atlas of epigenetic changes in the aging mouse brain, revealing how DNA methylation, genome structure, and gene activity change across brain regions and cell types. The atlas has already shown clear epigenetic differences between different age groups and allowed the development of ...
A new study found that functional impairment worsened over time in individuals with early Parkinson's disease, despite plateaued symptoms, with gait, balance, and posture being the most bothersome issues. The study's results underscore the importance of incorporating real-world measures of disease progression in clinical trial design.
Researchers discover enzyme ANKIB1 crucial for innate immune signalling, driving type I and type III interferon induction. This finding solves a long-standing puzzle in innate immunity and provides opportunities for new therapies for devastating diseases.
A Mayo Clinic study found that women with abnormal Parkinson's-related protein levels accumulate Alzheimer's-related pathology faster, leading to faster disease progression. The study analyzed data from 415 participants and showed that women's brains progress up to 20 times faster than men's in this regard.
A new study reveals how defective dopamine packaging in neurons triggers toxic processes, leading to Parkinson's disease symptoms. Researchers discovered that delivering energy via ATP can repair packaging and halt damage.
A new study published in Neurology found that currently smoking is associated with a lower risk of developing Parkinson’s disease, but quitting smoking was associated with a lower risk of death. Researchers also found that sustained quitters had a 17% lower risk of death compared to persistent smokers.
Two gut bacteria, Akkermansia muciniphila and Bacteroides thetaiotaomicron, work together to destroy intestinal mucus, leading to dry and immobile stool. This discovery explains why standard treatments often fail for millions with chronic constipation, including those with Parkinson's disease.
Researchers develop novel method to manipulate cell structures using weak magnetic fields and isotopes, bridging structural biology, biophysics, and quantum biology. This work offers a potential new strategy for stabilizing damaged brain proteins, typical of neurodegenerative diseases.
Rice bioengineer Jerzy Szablowski has been awarded a Sloan Research Fellowship for his innovative work on noninvasive methods to communicate with the brain. He aims to develop versatile platform technologies to obtain new types of research data and treat multiple diseases.
Researchers from UC San Francisco successfully decoded brain activity patterns associated with walking, enabling the development of personalized neural biomarkers for movement state classification. This breakthrough could lead to more effective adaptive DBS systems that adjust stimulation in response to a patient's activity state.
Researchers found that Parkinson's patients experience weight loss due to selective fat depletion, not muscle loss, driven by impaired carbohydrate-based energy production. This metabolic shift highlights a disorder of both the brain and body, driving disease progression.
A comprehensive roadmap identifies mouse models that incorporate aging as a central element of Parkinson's disease pathogenesis, fostering cooperation among researchers. The collaboration aims to make it easier for scientists to include aging in their efforts to tackle the incurable neurodegenerative motor disease.
A new software tool developed by MIT researchers can reliably and finely resolve eight distinct nerve bundles in live diffusion MRI scans, shedding light on neurodegenerative diseases like Parkinson's and Alzheimer's. The BrainStem Bundle Tool (BSBT) reveals distinct patterns of structural changes in patients with these conditions.
Researchers have identified a specific brain network that is mainly active in the fast beta frequency range and modulates motor symptoms of Parkinson's disease through deep brain stimulation. Stimulating this network, which communicates at 20-35 Hz, can improve motor symptoms in patients with Parkinson's disease.
Researchers at Keck Medicine of USC are investigating a unique therapy that uses lab-generated stem cells to repair damaged brain cells and produce dopamine, which may slow down the progression of Parkinson's disease. The treatment has shown promise in early clinical trials with 12 participants experiencing improved motor function.
A new study identifies the somato-cognitive action network (SCAN) as responsible for Parkinson's disease symptoms, which can be treated with non-invasive transcranial magnetic stimulation. Targeting this network improves symptoms more than twice as much as treatments targeting nearby brain areas.
Researchers found that overexpressed Fc gamma receptors on reactive microglia mistakenly identify healthy neurons, leading to their elimination. Immunotherapy targeting these receptors could slow disease progression by preserving dopaminergic neurons.
A team at Chalmers University of Technology has discovered biomarkers for Parkinson's disease in the blood, which could lead to early diagnosis via blood tests within five years. The study found distinct gene activities linked to DNA damage repair and stress response in patients in the early phase of the disease.
A new study reveals how Parkinson's spreads from the gut to the brain via immune cells, identifying a key role for gut macrophages in transporting toxic proteins. Reducing these cells can slow disease progression and improve motor symptoms in mice.
The AMALIA project develops a scalable screening platform to identify anti-amyloid therapies, bypassing the challenge of studying amyloid nucleation. This approach enables parallel discovery campaigns on multiple targets, offering unprecedented speed and scalability.
Researchers at UNIGE successfully determined the structure of abnormal protein deposits from a skin biopsy, paving the way for earlier diagnosis and potentially more accessible treatment options. The study's breakthrough opens up new avenues for studying neurodegenerative diseases, including Alzheimer's and Parkinson's.
A study reviews decades of research on Hsp70's role in neurodegenerative diseases, highlighting its protective effects and potential therapeutic value. The review reveals that different Hsp70 isoforms interact with co-chaperones and cellular pathways to determine protein clearance.
Researchers have characterized the association between cellular senescence and human brain structure in both development and late life. The study found that senescence-related gene expression is linked to brain volume and cortical organization, with distinct roles depending on cell type and stage of life.
A nationwide study found that Parkinson's disease is more common among individuals with higher socioeconomic status and in the northern provinces of the Netherlands. The risk increases with age, peaking between 75 and 85 years, and is higher among men.
A team of researchers found that intentionally raising and lowering blood CO2 levels through rhythmic exposure or controlled breathing may boost the glymphatic system's effectiveness. This approach could preserve brain function, improve cognition, and reduce cognitive decline in Parkinson's patients.
Researchers at the University of Virginia Health System have discovered how the keto diet protects against epilepsy seizures by regulating brain cell activity. The team found that a specific cellular receptor, HCAR2, plays a crucial role in reducing seizures, and may be targeted for new treatments.
Researchers highlight shared and distinct immune features between neurodegenerative and neuroimmune diseases, pointing to novel treatment strategies. The study suggests that a deeper understanding of Parkinson's disease immunology informed by lessons from multiple sclerosis may bridge the therapeutic gap for PD.
A new UCLA study combines human and animal research to identify chlorpyrifos as a potential environmental cause of Parkinson's disease. Long-term residential exposure to the pesticide increases the risk of developing the condition by more than 2.5 times.
A McGill-led study found dopamine does not set movement speed but acts as a support system that makes movement possible. Restoring dopamine to normal levels may be enough to improve movement and simplify Parkinson's treatment.
A mouse study by Okinawa Institute of Science and Technology researchers has found that acetylcholine release is essential for breaking habits and enabling new choices to be made. The study's findings may help understand diseases such as Parkinson's disease, addiction, and obsessive-compulsive disorder.
Researchers investigated a combination of stem cell therapy and BDNF enhancement to treat Parkinson's disease. The strategy aims to promote neuroregeneration and functional recovery by introducing progenitor cells genetically matched to the donors, while upregulating BDNF to mitigate neuronal loss and enhance motor function.
The International Linked Clinical Trials Program aims to change that by supporting and facilitating clinical trials of potentially disease-modifying treatments. Over 6,800 people with Parkinson's have participated in these trials, and approximately 40% of prioritized drugs have been approved for clinical trials.
Midbrain dopamine neurons create a glycogen fuel reserve but regulate it in a way that leaves them vulnerable to glucose shortages as they age. This vulnerability may explain the deaths of these neurons in Parkinson’s disease.
A new study found that aerobic exercise can increase dopamine release and improve motor performance in middle-aged mice, suggesting a potential link to improved mobility and reduced symptoms of Parkinson's disease. The research team plans to repeat the study in genetically engineered mice models for neurodegenerative disorders.
A new study published in the Journal of Alzheimer's Disease has shown that dance can be beneficial in halting cognitive decline associated with Parkinson's disease. The study found significant improvements in cognitive scores for participants who engaged in dance classes, compared to those who did not participate.
A new study highlights five ways microplastics can trigger inflammation and damage in the brain, including immune cell activity and oxidative stress. Microplastics weaken the blood–brain barrier, causing immune cells to attack them and leading to further damage.
The EBRAINS Summit 2025 will bring together experts to assess how neuroscience can drive medical progress, digital innovation, and responsible data use. Preliminary results from the EPINOV clinical trial, integrating virtual brain technology for epilepsy surgery planning, will be presented.
A large Korean cohort study reveals a link between restless legs syndrome and Parkinson's disease, highlighting opportunities for early detection. Dopamine-agonist therapy may reduce the risk of developing PD in RLS patients, according to the study's findings.
Studies have confirmed that liquid droplets formed by ubiquilin-2 (UBQLN2) facilitate the aggregation and fibril formation of α-synuclein protein. Researchers also discovered a compound that interacts with UBQLN2, preventing its self-association and liquid droplet formation, which may lead to new treatments for neurodegenerative diseases.
A new study examining millions of electronic health records suggests a strong link between untreated obstructive sleep apnea and an increased risk of developing Parkinson's disease. Researchers found that those with untreated sleep apnea were nearly twice as likely to develop Parkinson's as those who treated it with CPAP.
A recent University of Michigan study sheds light on the critical protein Sarm1, which controls both nerve breakdown and regeneration. The research found that blocking Sarm1 boosts nerve regeneration but only if it preserves a delicate balance between protection and repair.
Researchers have successfully engineered functional brain-like tissue without animal-derived materials, opening doors to more controlled and humane neurological drug testing. The new material functions as a scaffold for donor brain cells and can be used to model traumatic brain injuries or neurological diseases like Alzheimer's.
A study from Gladstone Institutes finds that dysfunctional mitochondria can initiate Parkinson's disease. The researchers used a unique mouse model to demonstrate the link between mitochondrial dysfunction and energy breakdown in cells, shedding light on potential new treatments.
Researchers at UGA engineered a live bacterium to deliver Levodopa steadily from the gut to the brain, alleviating motor deficits in models of Parkinson's disease. This breakthrough could lead to fewer pills, steadier symptom control, and better quality of life for patients.
The UT Health San Antonio Center for Brain Health is a $100 million facility that brings together clinical care, diagnostics and research under one roof. The center will redefine treatment of conditions including Alzheimer's, dementia, stroke and Parkinson's with multidisciplinary care teams.
A nonsurgical approach has been demonstrated to quiet a specific brain circuit in an animal model by delivering engineered gene therapy only to the targeted region. The method uses low-intensity focused ultrasound to open the blood-brain barrier, allowing precise control over brain activity without impacting off-target areas.
A team of researchers from Rice University and the Houston Methodist Research Institute will study how the brain responds to neural implants. They aim to develop more stable and longer-lasting brain-computer interfaces and neuroprosthetics, which could treat neurological disorders such as Parkinson’s disease, epilepsy, and stroke.
A U-M-led team is working to minimize latency in virtual and augmented reality games for people with Parkinson's disease. They are developing two games: an adaptive soccer game and a word game that enables players to fight the progression of the disease through physical and cognitive exercise.
Researchers at OIST discover a common molecular cascade disrupting brain signaling in both Alzheimer's and Parkinson's diseases. They identify a shared mechanism affecting synaptic vesicle recycling, leading to impaired communication between brain cells.
High-volume noise exposure in a mouse model of early-stage Parkinson's disease slowed movement and reduced balance, suggesting a connection between sound processing and movement areas. Chronic noise exposure mimicked Parkinsonian symptoms by damaging dopamine-producing cells.
The study identified dozens of genetic regions that influence the size and thickness of the corpus callosum and its subregions. The research team created an AI-powered tool that finds and measures the corpus callosum in brain MRI scans automatically, allowing for unprecedented analysis of brain structure at scale and precision.
Researchers built a comprehensive atlas of the developing human brain, capturing nearly every cell type and their genetic fingerprints. The study provides a precise benchmark for testing new therapies for Parkinson's disease and other neurological conditions.
A new study found that alpha-synuclein triggers early gene expression changes in a Parkinson's disease model, revealing brain region-specific and systemic transcriptomic alterations. These changes may contribute to disease development and serve as potential biomarkers.
New research from the University of South Australia highlights the need for personalized, multidisciplinary and empathetic care for people with Parkinson's disease. Researchers found that gaps in support lead many individuals to rely on trial-and-error approaches to manage their pain, resulting in reduced quality of life.
Researchers have developed a blood test that detects Parkinson's disease by analyzing the activity of immune cells. The study found 22 genes whose expression was altered in patients with Parkinson's, suggesting potential diagnostic markers and insights into the disease's mechanisms.
Case Western Reserve University researchers discovered pseudo leukotrienes, which may be the dominant players in the inflammatory cascade that causes disease. The findings open new avenues for treating asthma and other inflammatory diseases.